Lifescan May Be Misleading Customers About SureStep Recall, FDA Says
This article was originally published in The Gray Sheet
Executive Summary
Purchasers of Lifescan's SureStep home glucose monitors may be "misled" by the firm's recall, which the Johnson & Johnson subsidiary "has characterized...as a product replacement program," FDA cautioned in a July 28 press release following up the company's June 4 Class I recall.
You may also be interested in...
LifeScan Defective SureStep Glucose Meter Civil Trial Slated For September
Johnson & Johnson subsidiary LifeScan will remain on probation for a three-year period, during which FDA and the U.S. Probation Office will oversee the firm's documentation of medical device reporting (MDR) complaints.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.